105350-42-3

Basic information

• Product Name: 4-(pyridin-4-ylmethoxy)aniline
• Synonyms: 4-(pyridin-4-ylmethoxy)aniline;Benzenamine, 4-(4-pyridinylmethoxy)-
• CAS NO: 105350-42-3
• Molecular Formula: C₁₂H₁₂N₂O
• Molecular Weight: 200.23648
• Mol File: 105350-42-3.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• CAS DataBase Reference: 4-(pyridin-4-ylmethoxy)aniline(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(pyridin-4-ylmethoxy)aniline(105350-42-3)
• EPA Substance Registry System: 4-(pyridin-4-ylmethoxy)aniline(105350-42-3)

Safety Data

• Hazardous Substances Data: 105350-42-3(Hazardous Substances Data)

Upstream product

• 936801-51-3 tert-butyl N-[4-(4-pyridylmethoxy)phenyl]carbamate 
• 252918-98-2 4-(4-nitro-phenoxymethyl)-pyridine 

Downstream Products

• 1596360-55-2 methyl 6-[[2,5-dioxo-3-[4-(4-pyridylmethoxy)phenyl]imidazolidin-1-yl]methyl]-7-methyl-pyrrolo[2,3-d]pyrimidine-2-carboxylate 
• 1596360-04-1 1-[4-(4-pyridylmethoxy)phenyl]imidazolidine-2,4-dione 
• 1596360-35-8 N-[(1S)-5-amino-1-cyano-pentyl]-6-[[2,5-dioxo-3-[4-(4-pyridylmethoxy)phenyl]imidazolidin-1-yl]methyl]-7-methyl-pyrrolo[2,3-d]pyrimidine-2-carboxamide 
• 1596360-78-9 9H-fluoren-9-ylmethyl N-[(5S)-5-cyano-5-[[6-[[2,5-dioxo-3-[4-(4-pyridylmethoxy)phenyl]imidazolidin-1-yl]methyl]-7-methyl-pyrrolo[2,3-d]pyrimidine-2-carbonyl]amino]pentyl]carbamate 
• 1596360-91-6 ethyl 2-[[4-(4-pyridylmethoxy)phenyl]amino]acetate 
• 936801-56-8 2-methyl-5-nitro-nicotinic acid 4-(pyridin-4-ylmethoxy)-phenyI ester 

Relevant articles and documents

Pyrrolopyrimidine-inhibitors with hydantoin moiety as spacer can explore P4/S4 interaction on plasmin

In the development of plasmin inhibitors, a novel chemotype, pyrrolopyrimidine scaffold possessing two motifs, a hydantoin-containing P4 moiety and a warhead-containing P1 moiety, is uncovered. A unique feature of the new line of the plasmin inhibitors is

BICYCLOSULFONYL ACID (BCSA) COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS

This invention pertains generally to the field of therapeutic compounds, and more particularly, to certain bicyclosulfonyl acid (BCSA) compounds which act as inhibitors of Tumour Necrosis Factor-α Converting Enzyme (TACE). The compounds are useful in the

BISAMIDE CYTOKINE INHIBITORS

The present invention provides low molecular weight compounds useful as cytokine inhibitors, and compositions thereof. In particular, compounds of the invention are bisamides and are useful as anti-inflammatory agents. In one aspect the compounds have the

DIARYL UREA DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES

The invention relates to the use of diaryl urea derivatives in the treatment of protein kinase dependent diseases or for the manufacture of pharmaceutical compositions for use in the treatment of said diseases, methods of use of diaryl urea derivatives in the treatment of said diseases, pharmaceutical preparations comprising diaryl urea derivatives for the treatment of said diseases, diaryl urea derivatives for use in the treatment of said diseases, novel diaryl urea derivatives, pharmaceutical preparations comprising these novel diaryl urea derivatives, processes for the manufacture of the novel diaryl urea derivatives, the use or methods of use of the novel diaryl urea derivatives as mentioned above, and/or these novel diaryl urea derivatives for use in the treatment of the animal or human body.

2-quinolinyl methoxy compounds, medical uses and intermediates therefor

The present invention relates to compounds of formula STR1 in which formula I X stands for O, S, STR2 R1 and R2 which can be the same or different stand for hydrogen, straight or branched, saturated or unsaturated, unsubstituted or substituted C1- C8 -alkyl, aryl or for ar-C1 -C4 -alkyl, aryl and ar being unsubstituted or substituted phenyl; R3, R4, R5, and R6 are the same or different and stand for hydrogen, halogen, pseudo halogen, cyano, nitro, amino, carboxy, hydroxy, alkyl, alkoxy; or R5 and R6 form an aromatic ring which is fused to the pyridyl ring, and which aromatic ring may substituted; provided that R1 and R2 cannot be hydrogen at the same time, and provided that when R5 and R6 both are chlorine and R1 is hydrogen, then R2 cannot be n-propyl; and salts and bioreversible derivatives thereof. The compounds of formula I are useful in the human and veterinary therapy, as they exert specific 5-lipoxygenase inhibition.

Pyridyl and quinoline derivatives

The present invention relates to compounds of formula I STR1 in which formula I X stands for O, S, STR2 R1 and R2 which can be the same or different stand for hydrogen, straight or branched, saturated or unsaturated, unsubstituted or